



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of James Martin LENHARD

Serial No.: 09/889,471

Art Unit: 1648

Filing Date: July 17, 2001

Examiner: Parkin, Jeffrey S.

For:

Methods Of Screening Protease Inhibitors, Of Inducing Mice Susceptible To HIV Protease Inhibitor-Induced Dyslipidemia, and Genes

Associated Therewith

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] Copies of the references are enclosed

[ ] Copies of the references were submitted in parent application Serial No. \_\_\_\_\_\_. (37 CFR 1.98(d))

[X] A copy of the European Search Report which issued on European Application No. <u>00905651.6</u> is submitted herewith. All of the publications cited in the European Search Report are listed on the attached form PTO-1449.

A. [ ] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[ ] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. [X] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311,

whichever occurs first.

**CERTIFICATE OF MAILING (37 CFR 1.8)** 

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: October 21, 2004

Marjorie V. Pfeiffer

| [X]     |                       | Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.  |  |  |  |  |
|---------|-----------------------|---|--|--|--|--|
|         |                       | Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).  |  |  |  |  |
| 1<br>i: |                       | The Information Disclosure Statement transmitted herewith is being filed <b>after</b> a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.   |  |  |  |  |
|         | In acco               | rdance with the requirements of 37 CFR 1.97(d):   |  |  |  |  |
|         | [ ]                   | Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]   |  |  |  |  |
|         | [ ]                   | Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and |  |  |  |  |
|         | [ ]                   | The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.  |  |  |  |  |
| (X<br>] | [] Please<br>] A dupl | charge any required fees to Deposit Account No.07-1392. licate copy of this paper is attached.  |  |  |  |  |
|         |                       | Respectfully Submitted,   |  |  |  |  |
|         |                       |   |  |  |  |  |

Michael M. Conger Attorney of Record Registration No. 43,562

Date: October 2, 2004

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2474 Facsimile: (919) 483-7988

| APPLICANT James Martin LENHARD  FILING DATE July 17, 2001  U.S. PATENT DOCUMENTS  Filing Date  | FORM PTO   |  | DISCLOSURE ST                     | ATEMENT                         |           | ATTORNEY DO<br>PU3610USw              | OCKET NO.      | SERIAL N<br>09/889,471 | SERIAL NO.<br>09/889.471   |  |  |
|--|--|--|-----------------------------------|---------------------------------|-----------|---------------------------------------|----------------|------------------------|----------------------------|--|--|
| Patent   Initials   Patent   Insumer   Patent   Initials   Name   Class   Subclass   If Appropria  |  |  |                                   |                                 | ľ         |                                       |                |                        |                            |  |  |
| U.S. PATENT DOCUMENTS    Patent   Issue Date   Name   Class   Subclass   Filing Date   If Appropriate   Patent   Number   Continue on page   Conti |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| Examiner Initials  Patent Number    Issue Date   Name   Class   Subclass   If Appropria  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| Patent   Issue Date   Name   Class   Subclass   Filing Date   If Appropria   If   |  |  |                                   |                                 |           |                                       |                | 1648                   |                            |  |  |
| Patent Number   Issue Date   Name   Class   Subclass   If Appropris  |  |  | <del></del>                       | U.S. PAT                        | ENT DO    | CUMENTS                               | _              |                        |                            |  |  |
| Continue on page   FOREIGN PATENT DOCUMENTS   Translation   Number   Date   Country   Class   Subclass   Translation   Ves   No  |  |  |                                   | Issue Date                      |           | Name                                  | Class          | Subclass               | Filing Date If Appropriate |  |  |
| Continue on page   FOREIGN PATENT DOCUMENTS   Translation   Number   Date   Country   Class   Subclass   Translation   Ves   No  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| Continue on page   FOREIGN PATENT DOCUMENTS   Translation   Number   Publication   Date   Country   Class   Subclass   Ves   No   Number   Date   Country   Class   Subclass   Ves   No   Number   Country   Class   Subclass   Ves   No   Number   Country   Class   Subclass   Ves   No   Country   Class   Subclass   Class   No   Country   Class   Clas   | 40/  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| Continue on page   FOREIGN PATENT DOCUMENTS   Translation   Number   Publication   Date   Country   Class   Subclass   Translation   Ves   No  | <u> </u>   |  |                                   |                                 |           |                                       | <u> </u>       |                        |                            |  |  |
| Continue on page FOREIGN PATENT DOCUMENTS  Document Number Publication Date Country Class Subclass Translation Number Onter Country Class Subclass Pes I No  OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agenists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "protease inhibitors and adipocyte differentiation in cell culture," Lancer 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., "Gentoriuses opportunistic infect," abstract 666, Onlinel (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Onlinel (Jan. 31, 1999 – Feb. 4, 1999).  10. Nichols et al., "Conf. Retroviruses opportunistic infect," abstract 666, Onlinel (Jan. 31, 1999 – Feb. 4, 1996).  11. Paulik et al., "Conf. Retroviruses opportunistic infect," abstract 666, Onlinel (Jan. 31, 1999 – Feb. 4, 1996 on uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has p | 4 10   | ļ  | ļ                                 |                                 |           | · · · · · · · · · · · · · · · · · · · |                |                        |                            |  |  |
| Continue on page   FOREIGN PATENT DOCUMENTS   Translation   Number   Publication   Date   Country   Class   Subclass   Translation   Yes   No  | <u>_\$</u> /   | <b>-</b>   | ļ                                 |                                 |           |                                       |                |                        | ļ                          |  |  |
| Document Number   Publication   Publicatio   | <u>*</u>   | <u> </u>   | <u> </u>                          |                                 |           |                                       |                |                        | <u> </u>                   |  |  |
| Document Number   Publication   Country   Class   Subclass   Translation   Ves   No  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| Number Date Country Class Subclass Yes   No  |  | <del> </del>   | Document                          |                                 | AIENI     | DOCUMENTS                             | ı              |                        | Translation                |  |  |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., "Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retine effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1995).  10. Nichols et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1995).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12 |  |  |                                   |                                 | <u>C</u>  | ountry                                | Class          | Subclass               |                            |  |  |
| OTHER DOCUMENTS (Including Author, Titte, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 195 10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  10. Nichols et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on li |  | <u> </u>   |                                   |                                 |           |                                       |                |                        |                            |  |  |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., "Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retine effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1995).  10. Nichols et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1995).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12 |  | ╁  |                                   |                                 |           |                                       |                | <del></del>            |                            |  |  |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 195 10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  10. Nichols et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on li |  | <u> </u>   |                                   |                                 |           | <del></del>                           |                |                        | <u> </u>                   |  |  |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., "Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retine effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1995).  10. Nichols et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1995).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12 |  | ╂  |                                   |                                 |           | ·                                     |                |                        |                            |  |  |
| OTHER DOCUMENTS (Including Author, Titte, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 195 10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  10. Nichols et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on li |  | <del>                                     </del>   |                                   |                                 |           |                                       |                |                        |                            |  |  |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  1. Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 195 10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  10. Nichols et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on li |  | I  |                                   | Conti                           | nue on n  | 10e                                   |                |                        | <u> </u>                   |  |  |
| <ol> <li>Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).</li> <li>Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).</li> <li>Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists.1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).</li> <li>Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).</li> <li>James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).</li> <li>Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).</li> <li>Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).</li> <li>Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retine effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 195</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir</li></ol>  |  |  | OTHER DOCUM                       |                                 |           |                                       | te. Page Num   | ber. Etc.)             |                            |  |  |
| and optimization of the phenyl alkyl ether moiety," Journal of Medicinal and Pharmaceutical Chemistry 41:5037-5054 (1998).  2. Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352(9133):1032 (Sep. 1998).  3. Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists.1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retine effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 199).  10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).  |  | 1.   |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ol> <li>(Sep. 1998).</li> <li>Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. I. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," <i>Journal of Medicinal Chemistry</i> 41(25):5020-50 (1998).</li> <li>Jain et al., "Metabolic complications associated with antiretroviral therapy," <i>Antiviral Research</i> 51(3):151-177 (Sep. 2001).</li> <li>James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," <i>AIDS Treatment News</i> 315: 4 (Mar. 1999).</li> <li>Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," <i>Proc. Nat'l. Acad. Sci. USA</i> 9(94):4318-4323 (Apr. 1997).</li> <li>Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," <i>Biochemical Pharmacology</i> 54(7):801-808 (1997).</li> <li>Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," <i>Aidsline</i> (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1991).</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," <i>Analytical Biochemistry</i> 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," <i>Cell and Tissue Research</i> 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," <i>AIDS</i> 12(16):2236-2237 (Nov. 1998).</li> </ol>   |  |  | and optimization 41:5037-5054 (19 | of the phenyl alkyl et<br>198). | ther moie | ety," Journal of M                    | edicinal and I | Pharmaceutico          | al Chemistry               |  |  |
| potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1991).  10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).   | <ol> <li>Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," Lancet 352 (Sep. 1998).</li> </ol>  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):5020-50 (1998).  4. Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3):151-177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1991).  10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).   | <ol> <li>Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel seri potent antihyperglycemic and antihyperlipidemic agents," Journal of Medicinal Chemistry 41(25):50 (1998).</li> <li>Jain et al., "Metabolic complications associated with antiretroviral therapy," Antiviral Research 51(3 177 (Sep. 2001).</li> <li>James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment New</li> </ol> |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| 177 (Sep. 2001).  5. James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).  6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).  7. Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).  8. Lenhard et al., inimavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).  9. Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1991).  10. Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  11. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared whumans," AIDS 12(16):2236-2237 (Nov. 1998).  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ol> <li>James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," AIDS Treatment News 315: 4 (Mar. 1999).</li> <li>Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).</li> <li>Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).</li> <li>Lenhard et al., indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retinol effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1991).</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared whumans," AIDS 12(16):2236-2237 (Nov. 1998).</li> </ol>   |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ol> <li>Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," Proc. Nat'l. Acad. Sci. USA 9(94):4318-4323 (Apr. 1997).</li> <li>Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).</li> <li>Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1991).</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared whumans," AIDS 12(16):2236-2237 (Nov. 1998).</li> </ol>   |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ol> <li>Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," Biochemical Pharmacology 54(7):801-808 (1997).</li> <li>Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1990).</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).</li> </ol>  |  | 6. Kliewer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," <i>Proc. Nat'l. Acad. Sci. USA</i> <b>9(94)</b> :4318-4323 (Apr. 1997). |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ol> <li>Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retino effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1990).</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared whumans," AIDS 12(16):2236-2237 (Nov. 1998).</li> </ol>  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ol> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 199</li> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).</li> </ol>  | <ol> <li>Lenhard et al., Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retine effects in vitro," Aidsline (Jan. 31, 1999 – Feb. 4, 1999).</li> <li>Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 – Feb. 4, 1990).</li> </ol>   |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| <ul> <li>Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated recept gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).</li> <li>Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).</li> <li>Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).</li> </ul>   |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue Research 290(1):79-87 (1997).  12. Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared w humans," AIDS 12(16):2236-2237 (Nov. 1998).   | gamma ligand binding domain," Analytical Biochemistry 257(2):112-119 (Mar. 1998).  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| humans," AIDS 12(16):2236-2237 (Nov. 1998).  | -  | uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," Cell and Tissue   |                                   |                                 |           |                                       |                |                        |                            |  |  |
| Continue on page   |  | 12.  |                                   |                                 |           |                                       | and insulin se | nsitivity in rat       | ts compared with           |  |  |
|  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |
| EXAMINER DATE CONSIDERED   | EXAMINER   | -  |                                   |                                 |           |                                       | DATE           | CONSIDERE              | D                          |  |  |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.  |  |  |                                   |                                 |           |                                       |                |                        |                            |  |  |